
illicit trade currenc movement gener
updat fda menthol youth initi focu
recent attend fdli confer heard fda commission dr
scott gottlieb interact member fda center tobacco product menthol
cigarett key fda focu youth initi cigarett electron
nicotin deliveri system end consid iqo compel end platform
far posit pm altria still expect fda approv us launch time
remain unclear juul also strong consum traction face fda scrutini
though expect inappropri find like bat compet global
iqo juul greatest menthol headlin risk exposur
menthol cigarett us volum drive global profit
menthol fda focu fda commission gottlieb indic focu
attent year go character flavor remain
combust tobacco product includ menthol cigarett fda didnt take action
menthol cigarett opportun remain us ad flavor
problem entic kid initi cigarett menthol may make easier
hook young smoker legal author public health oblig
address risk product standard ban menthol cigarett would
take sever year support effort seem clear remark
youth appeal complic issu dr gottlieb said fda would take
escal seri action includ compani market end way
may deliber entic youth fda rightli concern
youth appeal one inher difficulti degre teen often attract
adult product flavor kiddi one flavor often cite driver
youth appeal initi juul top two sell flavor cool mint virginia
tobacco total sale neither gener cite youth appeal
also compar juul us sale trajectori iqo japan chart insid
recent fda action may eas polit pressur fda recent cite retail
end sale minor request market inform juul
action may help eas polit pressur gottlieb tone still firm ad
dont get inform demand document rais new question well
explor option includ enforc action know fda
receiv consid juul publicli visibl step appropri pledg
fight underag use product ceo reiter mission elimin
cigarett smoke throughout world market approach matter juul
instagram feed exampl emphas switch smoke appar
youth content websit strict age verif procedur on-line sale
talk fda consist expect iqo approv surprisingli
broad consensu among mani industri regulatori tobacco control repres
around opportun provid end altern smoker continu
expect long difficult path regulatori chang combust cigarett
especi nicotin level expect end momentum continu ask
fda pmta process time iqo agenc acknowledg
behind schedul still learn process gave us reason
believ delay caus concern though target time given
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
juul
compar iqo
compar juul us market share cigarett plu stick equival juul pod
iqo share histori japan use cigarett plu iqo heatstick categori total
start quarter first hit market share level
iqo japan quarterli share vs juul us share use share level quarter one
howev shift juul histori one quarter trend look similar iqo
japan suggest juul could posit perhap signific market share
gain maintain trajectori still somewhat earli monitor trend
iqo japan quarterli share vs juul us share juul histori shift one quarter
page
japanjuul japanjuul us still expect iqo
approv come
label come
fda commit reduc risk product remain clear dr gottlieb indic
intent tri transit smoker quickli combust tobacco onto reduced-risk
product reiter distinct combust nicotin fdli event
nicotin complet benign substanc isnt caus death diseas
associ tobacco use combust associ toxin consid
posit iqo approv prospect especi given flavor profil iqo typic
tobacco flavor tobacco menthol tobacco aerosol sourc believ
increas appeal smoker decreas youth posit regulatori outlook
begin august end requir two primari panel cover
warn label bigger cigarett focu addict
nicotin warn begin product contain nicotin may help address
concern user specif youth unawar nicotin end one
risk howev confus around nicotin effect public believ nicotin
caus cancer fda indic effort underway chang mispercept
page
rate pm overweight target price appli multipl ep
expect pmi deliv three-year averag organ sale growth
increas stronger us dollar growth counterfeit product could pose risk upsid
share
rate mo overweight target price ep
current multipl ep expect altria deliv three-year averag sale
growth averag ep growth risk unfavor regulatori action disrupt excis
tax increas growth counterfeit product unexpect competitor price cut could neg
rate imb ln neutral target price ep expect
imperi averag organ sale growth fiscal year compound annual ep
growth fiscal year risk disrupt excis tax macro pressur currenc
move may pose risk profit
rate bat ln neutral target price appli multipl ep
expect bat deliv three-year averag organ sale growth
averag ep growth risk disrupt excis tax macro pressur currenc move may
pose risk profit
page
